{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/","result":{"pageContext":{"chapter":{"id":"fe019c79-fed9-53d2-872f-da771bf12db0","slug":"cvd-risk-less-than-10percent","fullItemName":"Scenario: CVD risk less than 10%","depth":2,"htmlHeader":"<!-- begin field 7538a06a-dc93-45a8-acca-d7110d189e5f --><h2>Scenario: Management of people with an estimated CVD risk less than 10%</h2><!-- end field 7538a06a-dc93-45a8-acca-d7110d189e5f -->","summary":"Covers management of people with a CVD risk score of less than 10%.","htmlStringContent":"<!-- begin item 6c436a4a-e7ad-4464-9ea3-1c1170cfa587 --><!-- begin field 02cf9225-0b96-4c6b-ad40-acbd0087065f --><p>From age 18 years onwards.</p><!-- end field 02cf9225-0b96-4c6b-ad40-acbd0087065f --><!-- end item 6c436a4a-e7ad-4464-9ea3-1c1170cfa587 -->","topic":{"id":"523d2a2f-e844-578d-a561-3be5cbca9b75","topicId":"f6d3b04f-1af7-4be9-8156-7728560d7626","topicName":"CVD risk assessment and management","slug":"cvd-risk-assessment-management","lastRevised":"Last revised in August 2020","chapters":[{"id":"7b4828f7-b87a-5825-8965-8fdd9129683e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e7373cf1-b9a1-5687-9711-2cb9d9c89c69","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"792673f1-3d99-54ef-99fe-bba0e1a561a8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b2dea30b-fe5c-5016-a74a-657f491fbc6d","slug":"changes","fullItemName":"Changes"},{"id":"78c4178a-c12b-5c09-b381-a13caf2b0555","slug":"update","fullItemName":"Update"}]},{"id":"a448bfdb-c0ae-515d-94a0-ff7ca675cdb6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"44aa879e-615a-5bce-88b8-8723ea0ccd5e","slug":"goals","fullItemName":"Goals"},{"id":"6fc1588f-7ff7-56a8-99ea-47cc099b05d5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1171d2a1-75d7-533d-b720-0492fc8b1eb3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a295e1e8-68f8-5f7f-9079-8b86314aae02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"80b984d3-485b-5103-b839-49a12de3708b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a72588c2-75b2-5fb4-8a3b-3a4ee9deb056","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7f7061ef-3615-572d-b80c-49d0441b7029","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7a402468-6c9d-5c65-aa94-ac4fba3efa6f","slug":"definition-of-cvd","fullItemName":"Definition of CVD"},{"id":"86b5e37a-5729-5a1a-8cdb-ce876c2f63ff","slug":"burden-of-cvd","fullItemName":"Burden of CVD"},{"id":"564a5209-6b9c-5f0d-b4e2-44fffe6a13e2","slug":"risk-factors-for-cvd","fullItemName":"Risk factors for CVD"},{"id":"95b341d8-0988-5dcd-9b67-e51b4e310ab8","slug":"strategies-for-cvd-prevention","fullItemName":"Strategies for CVD prevention"}]},{"id":"7ef7e02f-cdf3-5561-87d6-387b8c85c6fe","fullItemName":"Management","slug":"management","subChapters":[{"id":"e351979f-6e51-53cf-9377-6933a02382e6","slug":"cvd-risk-assessment","fullItemName":"Scenario: CVD risk assessment"},{"id":"fe019c79-fed9-53d2-872f-da771bf12db0","slug":"cvd-risk-less-than-10percent","fullItemName":"Scenario: CVD risk less than 10%"},{"id":"7815dd8b-1e90-5da1-8f71-d11a3b4d0454","slug":"cvd-risk-10percent-or-more","fullItemName":"Scenario: CVD risk 10% or more"}]},{"id":"4bca1eaa-45f6-5ef6-8e61-9fcdd7be2974","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4365c311-267f-5090-b1a7-5ca71f0a5e8b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e8349012-8164-5323-bd10-3c52e461fbd4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"09e44952-956e-5e91-9f5b-b584c9c7340f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c76818be-b774-5f66-badd-b8b17ccd0eef","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a06dccb-9327-5792-a92c-1c8278cab678","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ff5c3303-e844-5444-9b71-dbe2fc774f83","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7a5af289-d6e5-5ded-92b0-696749f9ff11","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7ef7e02f-cdf3-5561-87d6-387b8c85c6fe","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e46af24e-bd70-5a28-8f28-b677a3cba20c","slug":"overview","fullItemName":"Overview","depth":3,"htmlHeader":"<!-- begin field aa4cdcd6-9952-4b66-98cb-001fcc0951a0 --><h3>How should I manage people with a CVD risk of less than 10%?</h3><!-- end field aa4cdcd6-9952-4b66-98cb-001fcc0951a0 -->","summary":null,"htmlStringContent":"<!-- begin item 9eb7e33a-1d69-423f-8373-aacbe89ce800 --><!-- begin field 03bff39c-4796-45d8-a164-a1df647cb236 --><ul><li><strong>For people with an estimated cardiovascular disease (CVD) risk score of less than 10% using the QRISK assessment tool:</strong><ul><li>Advise that although the risk is low, further reductions in risk can often still be achieved. </li><li>Offer advice on any relevant <a class=\"topic-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/#lifestyle-advice\">lifestyle factors</a> that can be improved. </li><li>Consider reviewing any relevant <a class=\"topic-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/#managing-comorbidities\">comorbidities</a> that may not be optimally treated. </li><li>Advise that a further risk assessment should be considered in 5 years. </li></ul></li><li><strong>Consider principles that may help a person to adopt a healthy lifestyle:</strong><ul><li>Find out what they know or have already been told about their risk of developing CVD, and how they feel about it. </li><li>Exploring their beliefs about what determines future health.</li><li>Assess their readiness, concerns, and confidence to make any changes to lifestyle.</li><li>Acknowledge that changing lifelong habits can be difficult and that gradual change that is sustained is often more permanent than a rapid change. </li><li>Be supportive of every improvement in lifestyle.</li><li>Where relevant, engage support from their family.</li><li>Accept that some people need support for a long time and that repeated efforts to encourage and maintain lifestyle change may be necessary. </li></ul></li></ul><!-- end field 03bff39c-4796-45d8-a164-a1df647cb236 --><!-- end item 9eb7e33a-1d69-423f-8373-aacbe89ce800 -->","subChapters":[{"id":"e95d0096-ee71-584a-8137-9072bc323ad7","slug":"basis-for-recommendation-537","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 130cb8cd-b3c6-4e77-80b3-14b8bc812cf5 --><h4>Basis for recommendation</h4><!-- end field 130cb8cd-b3c6-4e77-80b3-14b8bc812cf5 -->","summary":null,"htmlStringContent":"<!-- begin item 537895a4-175f-4726-bd86-56594f805447 --><!-- begin field 8e2d65c2-40e1-4e5e-bfd9-040115ca1d1f --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">NICE, 2016</a>], the Public Health England (PHE) <em>NHS Health Check: Best practice guidance</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">PHE, 2017</a>], European Society of Cardiology (ESC) <em>2016 </em><em>European guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">ESC, 2016</a>], and a handbook commissioned by the UK National Screening Committee <em>The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management </em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">UK National Screening Committee, 2012</a>].</p><!-- end field 8e2d65c2-40e1-4e5e-bfd9-040115ca1d1f --><!-- end item 537895a4-175f-4726-bd86-56594f805447 -->","subChapters":[]}]},{"id":"b75fbd15-490b-5c6d-add5-db729835d260","slug":"lifestyle-advice","fullItemName":"Lifestyle advice","depth":3,"htmlHeader":"<!-- begin field 564828fd-f858-4b3e-8f9a-cfe2fc91957e --><h3>What lifestyle advice should I give to help reduce the risk of CVD?</h3><!-- end field 564828fd-f858-4b3e-8f9a-cfe2fc91957e -->","summary":null,"htmlStringContent":"<!-- begin item 5dc958a9-dfd3-4c81-b74b-4a2d51f5aacd --><!-- begin field 2055a002-e852-44fd-85a6-b705c3dcf91c --><ul><li><strong>Give lifestyle advice to all people who have had a cardiovascular disease (CVD) risk assessment, regardless of their risk score. </strong></li><li><strong>Advise that most people, if not all, will be able to reduce whatever risk they have of developing CVD by relevant changes to lifestyle </strong>—<strong> </strong>the three most important modifiable and causal CVD risk factors are smoking, hypertension and abnormal lipids.</li><li><strong>Advise smokers to stop and non-smokers to avoid passive smoking. </strong><ul><li>Offer support for people who want to stop smoking and include referral to an NHS Stop Smoking Service. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li></ul></li><li><strong>Advise weight loss if the person is overweight or obese: </strong><ul><li>Offer appropriate advice and support to help them work towards a healthy weight (for example, achieving and maintaining a weight loss target of 3 kg).</li><li>If obese, also assess for symptoms of sleep apnoea, and treat if appropriate — for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> and <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>.</li></ul></li><li><strong>Advise the person to adopt a diet that helps to reduce CVD risk, including:</strong><ul><li><strong>Eating: </strong><ul><li>Unsalted nuts, seeds and legumes — at least 4 to 5 portions per week (one portion is about a handful or about 30 g).</li><li>Fish — at least two portions per week, including a portion of oily fish (pregnant women should limit their oily fish intake to no more than two portions per week and avoid marlin, shark, and swordfish).</li><li>Fruit and vegetables — at least 5 portions per day.</li><li>Fibre — 30-45g per day (choose wholegrain varieties of starchy foods).</li></ul></li><li><strong>Reducing:  </strong><ul><li>Sugar, and food products containing refined sugars, including fructose.</li><li>Saturated fat — total fat intake should be 30% or less of total energy intake, and saturated fat should be 7% or less).</li><li>Salt — it should be less than 6 g per day (it should not be added at the table, and processed foods should be kept to a minimum).</li></ul></li><li><strong>Increasing</strong> mono-unsaturated fat intake with olive oil or rapeseed oil or spreads based on these oils, and to use them in food preparation.<ul><li>Note: Dietary supplements including omega-3 capsules, plant sterols (sitosterol or sitostanol) or supplemented foods are not recommended as there is no good evidence that they reduce CVD risk.</li></ul></li></ul></li><li><strong>Advise the person to keep alcohol consumption within the recommended limits: </strong><ul><li>For men and women: no more than 14 units per week (spread over 3 days or more).<ul><li>For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/background-information/definition/#unit-of-alcohol\">Unit of alcohol</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.  </li></ul></li><li>Having at least two alcohol-free days per week.</li><li>Avoiding binge drinking and intoxication.</li><li>If alcohol use seems to be a problem, it should be specifically addressed — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li></ul></li><li><strong>Advise the person to be physically active and to avoid prolonged sedentary behaviour, including:</strong><ul><li>At least 75 minutes per week of vigorous intensity aerobic activity, or a mix of moderate and vigorous aerobic activity. </li><li>At least 150 minutes per week of moderate intensity aerobic activity (to the point of slight breathlessness), <em>or</em> </li><li>Muscle-strengthening activities on two or more days a week that work all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms).</li><li>Activity in bouts of 10 minutes or more is as effective as longer bouts so long as the total per week is as above. Moderate intensity activities include those that can be incorporated into everyday life such as brisk walking, using stairs, and cycling. </li><li>Encourage people who cannot manage moderate intensity physical activity because of comorbidity, medical conditions or personal circumstances to exercise to their maximum safe capacity. </li></ul></li></ul><!-- end field 2055a002-e852-44fd-85a6-b705c3dcf91c --><!-- end item 5dc958a9-dfd3-4c81-b74b-4a2d51f5aacd -->","subChapters":[{"id":"ca985615-de16-589c-9ba4-44aaae442d23","slug":"basis-for-recommendation-ee2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 09fadde1-c4cd-4eff-8633-7f2febbfe4f1 --><h4>Basis for recommendation</h4><!-- end field 09fadde1-c4cd-4eff-8633-7f2febbfe4f1 -->","summary":null,"htmlStringContent":"<!-- begin item ee260fcd-9c8f-4cb2-909e-3091953b432c --><!-- begin field e4d990f3-381f-40e9-8a2e-36bfacbb59fd --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">NICE, 2016</a>], the <em>UK Chief Medical Officers' low risk drinking guidelines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">DH, 2016</a>] the Public Health England (PHE) <em>NHS Health Check: Best practice guidance</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">PHE, 2017</a>], the European Society of Cardiology (ESC) <em>2016 European guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">ESC, 2016</a>], and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">SIGN, 2017</a>]. </p><!-- end field e4d990f3-381f-40e9-8a2e-36bfacbb59fd --><!-- end item ee260fcd-9c8f-4cb2-909e-3091953b432c -->","subChapters":[]}]},{"id":"8b203820-0609-500b-97b5-42b2c522e137","slug":"managing-comorbidities","fullItemName":"Managing comorbidities","depth":3,"htmlHeader":"<!-- begin field 2e9ef611-5b17-4e19-91fc-a76c012f0e0f --><h3>How should I manage comorbidities which are associated with increased risk of CVD?</h3><!-- end field 2e9ef611-5b17-4e19-91fc-a76c012f0e0f -->","summary":null,"htmlStringContent":"<!-- begin item e8396b3a-c7b6-4f32-92c1-a76c012f0c75 --><!-- begin field 724686ac-7c22-4653-8c61-a76c012f0e0f --><ul><li>Other medical conditions are associated with an increased risk of cardiovascular disease (CVD) — where possible, treatment should be optimized to reduce their effect on CVD risk, these include:<ul><li>Atrial fibrillation — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>. </li><li>Chronic kidney disease — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. </li><li>Diabetes mellitus — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>. </li><li>Dyslipidaemias, such as familial hypercholesterolaemia — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a>. </li><li>Hypertension — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>. </li><li>Obesity, especially if associated with obstructive sleep apnoea — for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> and <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>. </li><li>Periodontitis — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gingivitis-periodontitis/\">Gingivitis and periodontitis</a>. </li><li>Rheumatoid arthritis, systemic lupus erythematosus, and other systemic inflammatory disorders — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis</a>. </li><li>Serious mental health problems — for more information see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/psychosis-schizophrenia/\">Psychosis and schizophrenia</a> and <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder</a>. </li></ul></li></ul><!-- end field 724686ac-7c22-4653-8c61-a76c012f0e0f --><!-- end item e8396b3a-c7b6-4f32-92c1-a76c012f0c75 -->","subChapters":[{"id":"afa8ee1f-fe1d-5e82-8318-f930a595373a","slug":"basis-for-recommendation-90d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 65d628e6-196f-481f-b05f-a76c012f0e13 --><h4>Basis for recommendation</h4><!-- end field 65d628e6-196f-481f-b05f-a76c012f0e13 -->","summary":null,"htmlStringContent":"<!-- begin item 90de6a28-fdcc-46a3-b1aa-a76c012f0e13 --><!-- begin field 63e1c004-347f-4935-b78b-a76c012f0e13 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">NICE, 2016</a>], and the European Society of Cardiology (ESC) <em>2016 European Guidelines on cardiovascular disease prevention in clinical practice </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">ESC, 2016</a>].</p><!-- end field 63e1c004-347f-4935-b78b-a76c012f0e13 --><!-- end item 90de6a28-fdcc-46a3-b1aa-a76c012f0e13 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}